TRAX rises +33% premarket likely after FBRX M&A headlines. FBRX is being acquired by Argenx for its lead candidate FB102, a first-in-class a

TRAX rises +33% premarket likely after FBRX M&A headlines. FBRX is being acquired by Argenx for its lead candidate FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo (positive Phase 1B data reported July 9, 2026) and celiac disease. Note TRAX s a clinical-stage immunology company whose lead program, ANB033, is also a novel anti-CD122 antagonis